findmyKOL
Clinical trialNCT02344017CompletedPhase 1/PHASE2Interventional

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

SponsorOrion Corporation, Orion PharmaEnrollment23Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Finland
  • Helsinki University Central Hospital

    Helsinki, Finland

France
  • Institut Gustave Roussy

    Villejuif, France

Latvia
  • P. Stradins Clinical University Hospital

    Riga, Latvia

United Kingdom
  • Velindre Cancer Centre

    Cardiff, United Kingdom

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
28 Feb 2015
Primary completion
31 Jan 2019
Completion
31 Jan 2019
Last update posted
19 Dec 2019
Registered enrollment
23
Registry id
NCT02344017

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.